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【要約】 
 
 
 
 
A prospective comparative study of risperidone long-acting injectable for 
treatment-resistant schizophrenia with  
dopamine supersensitivity psychosis 
（ドパミン過感受性精神病を有する治療抵抗性統合失調症患者 
に対するリスペリドン持効性注射剤を用いた前向き研究） 
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Abstract 
Objective: Dopamine supersensitivity psychosis (DSP) is considered to be one cause of 
treatment-resistant schizophrenia (TRS). The authors investigated the efficacy of 
risperidone long-acting injections (RLAI) in patients with TRS and DSP. 
Method: This is a multicenter, prospective, 12-month follow-up, observational study 
that included unstable and severe TRS patients with and without DSP. 115 patients with 
TRS were recruited and divided into two groups according to the presence or absence of 
DSP which was judged on the basis of the clinical courses and neurological 
examinations. RLAI was administered adjunctively once every 2 weeks along with oral 
antipsychotics. We observed changes in scores for the Brief Psychiatric Rating Scales 
(BPRS), Clinical Global Impression-Severity of Illness (CGI-S), Global Assessment of 
Functioning Scale (GAF), and Extrapyramidal Symptom Rating Scale (ESRS) during 
the study. Of the assessed 94 patients, 61 and 33 were categorized into the DSP and 
NonDSP groups, respectively. 
Results: While baseline BPRS total scores, CGI-S scores and GAF scores did not differ, 
the ESRS score was significantly higher in the DSP group compared with the NonDSP 
group. Treatment significantly reduced BPRS total scores and CGI-S scores, and 
increased GAF scores in both groups, but the magnitudes of change were significantly 
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greater in the DSP group relative to the NonDSP group. ESRS scores were also reduced 
in the DSP group. Responder rates (≥20% reduction in BPRS total score) were 62.3% in 
the DSP group and 21.2% in the NonDSP group. 
Conclusions: It is suggested that DSP contributes to the etiology of TRS. Atypical 
antipsychotic drugs in long-acting forms, such as RLAI, can provide beneficial effects 
for patients with DSP. 
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